echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Innovative Chinese medicines have entered the harvest period, and 2 new drugs have been approved for marketing

    Innovative Chinese medicines have entered the harvest period, and 2 new drugs have been approved for marketing

    • Last Update: 2021-12-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
     It is understood that the research and development of innovative drugs is difficult, and innovative traditional Chinese medicines are "difficult to produce" due to the particularity of their products
    .
    Statistics show that in 2020, the State Food and Drug Administration has approved 48 innovative drugs to be marketed.
    There are only 3 traditional Chinese medicines.
    They are Lianhuaqing Cough Tablets from Ling Pharmaceutical, Muscle and Bone Analgesic Gel from Kangyuan Pharmaceutical, and Wuhe Boao The total alkaloid tablets of mulberry branches
    .
    Although the number is not large, it has been a year in which more new Chinese medicines have been approved in the past five years
    .
    It is worth noting that with the continuous improvement of the R&D strength of domestic pharmaceutical companies, the era of the outbreak of innovative Chinese medicine drugs is gradually coming
    .
    Recently, a number of innovative Chinese medicines have been approved for marketing one after another
    .
    On December 16, the State Drug Administration issued a notice of drug approval to market, announcing the approval of the market registration application for Huzhen Qingfeng Capsules and Jieyu Chufan Capsules
    .
    Statistics show that the listing of approved Huzhen breeze capsule, man-made Yili Pharmaceutical Co.
    , Ltd.
    holds
    .
    The drug is an innovative Chinese medicine developed on the basis of clinical experience.
    It has carried out a randomized, double-blind, placebo parallel controlled, multi-center clinical trial.
    The clinical trial research results show that it can be used for mild to moderate acute gouty arthritis in traditional Chinese medicine.
    Treatment of damp-heat accumulation syndrome
    .
    Jieyu Chufan Capsule is also an innovative traditional Chinese medicine developed on the basis of clinical experience.
    The prescription is based on Banxia Houpu Decoction recorded in the classic TCM book "The Synopsis of the Golden Chamber" and Zhizi Houpu Decoction recorded in "Treatise on Febrile Diseases" , Carried out randomized, double-blind, positive control drugs (chemical drugs), placebo parallel controlled, multi-center clinical trials, clinical trial research results showed that it can be used for mild to moderate depression TCM syndrome differentiation is Qi stagnation, phlegm obstruction, depression and fire internal disturbance Card treatment
    .
    Marketing authorization holder is Shijiazhuang Yiling Pharmaceutical Co.
    , Ltd
    .
    In addition to the above drugs, since November, four other innovative Chinese medicines have also been approved for marketing
    .
    Including Fangsheng Pharmaceutical’s Xuanqijian Bone Tablets, Phoenix Pharmaceutical’s Qizhi Yishen Capsules, Tasly’s Kunxinning Granules, and Kangyuan Pharmaceutical’s Class 1.
    1 New Drug Yinqiao Qingre Tablets
    .
    Among them, Xuanqijian bone tablets can be used to treat mild to moderate knee osteoarthritis in traditional Chinese medicine, which is a syndrome of stasis of tendons and veins; Qizhi Yishen capsule can be used for the treatment of early diabetic nephropathy syndrome of Qi and Yin; Kunxinning granules are Class 1.
    1 innovative Chinese medicine, once used as Kunyining granules, is indicated for female menopausal syndrome; Kangyuan Pharmaceutical's Yinqiao Qingre Tablets will provide a new treatment option for patients with exogenous wind-heat common cold
    .
    Industry analysts believe that the above results are in recent years.
    Through continuous promotion of the reform of the review and approval mechanism of Chinese medicines, the establishment and improvement of the registration management system and technical evaluation system in line with the characteristics of Chinese medicines, and the clinical value-oriented, accelerate the promotion of the development of new Chinese medicines, and the innovation of Chinese medicines The pharmaceutical field is constantly achieving new breakthroughs
    .
    According to the current development trend of innovative traditional Chinese medicines, the future innovative achievements of traditional Chinese medicines are expected to continue to emerge.
    By 2024, the market size of Chinese patent medicines in China is expected to reach 1,137.
    5 billion yuan
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.